Dr. Reddy's Laboratories Ltd. ADR diskutieren
Dr. Reddy's Laboratories Ltd. ADR
WKN: 659157 / Symbol: RDY / Name: Dr. Reddy's / Aktie / Pharmazeutika / Mid Cap /
?
2,61 %
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to an "underperform" rating.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target raised by analysts at Barclays PLC from $75.00 to $80.00. They now have an "overweight" rating on the stock.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target raised by analysts at Barclays PLC from $80.00 to $81.00. They now have an "overweight" rating on the stock.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target raised by analysts at Barclays PLC from $81.00 to $87.00. They now have an "overweight" rating on the stock.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target lowered by analysts at Barclays PLC from $17.40 to $17.00. They now have an "overweight" rating on the stock.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating. They now have a $16.90 price target on the stock, up previously from $14.44.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at Hsbc Global Res from a "hold" rating to a "strong-buy" rating.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories (RDY) was downgraded by The Goldman Sachs Group, Inc. from "neutral" to "sell".
Ratings data for RDY provided by MarketBeat
Neueste Beiträge
UBS_Group_AG in Thomson Reuters Corporation diskutieren